Haemonetics (HAE) Cash from Investing Activities Growth (3y) (2012 - 2026)

Haemonetics (HAE) Cash from Investing Activities Growth (3y) (2012 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Growth (3y) (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn -253.01%
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn -11.91%
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn -24.52%
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn -6.88%
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn -472.46%
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn -16.93%
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn -111.03%
8 Smith & Nephew 26.99 Bn 26.41 Bn - -
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn -
10 Haemonetics 3.78 Bn 3.54 Bn 198.21 Mn -68.81%

Historic Data

Download Data
DateValue
Mar 28, 2026 -68.81%
Dec 27, 2025 6.89%
Sep 27, 2025 0.65%
Jun 28, 2025 17.24%
Mar 29, 2025 36.13%
Dec 28, 2024 -3.96%
Sep 28, 2024 -4.43%
Jun 29, 2024 -106.31%
Mar 30, 2024 68.78%
Dec 30, 2023 -203.91%
Sep 30, 2023 -38.85%
Jul 1, 2023 13.88%
Apr 1, 2023 26.38%
Dec 31, 2022 -22.48%
Oct 1, 2022 -93.18%
Jul 2, 2022 -221.66%
Apr 2, 2022 -37.70%
Jan 1, 2022 17.55%
Oct 2, 2021 24.71%
Jul 3, 2021 16.54%